Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy

Foot and Ankle International

Volumn 25, Issue 5, 2004, Pages 331-335

  Bibbo, Christopher ^a,b,c   Goldberg, Jerry W ^a,b,c  

^a Marshfield Clinic ^*

^b MARSHFIELD CLINIC   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Complications; Etanercept; Healing; Infection; Infliximab; Orthopaedic Surgery; Rheumatoid Arthritis; Tumor Necrosis Factor Alpha

Indexed keywords

ETANERCEPT; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; STEROID; TUMOR NECROSIS FACTOR ALPHA; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGE; AGED; ARTICLE; CLINICAL ARTICLE; DRUG SAFETY; ELECTIVE ORTHOPEDIC FOOT AND ANKLE SURGERY; ELECTIVE SURGERY; FEMALE; FOLLOW UP; HUMAN; IMMUNOMODULATION; INFECTION RISK; INFECTIOUS COMPLICATION; INFORMATION PROCESSING; MALE; ORTHOPEDIC SURGERY; PERIOPERATIVE PERIOD; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SIDE EFFECT; SMOKING; WOUND HEALING; ANKLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFECT; FOOT; MIDDLE AGED; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; ANKLE; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FOOT; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; ORTHOPEDIC PROCEDURES; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; RISK FACTORS; SURGICAL PROCEDURES, ELECTIVE; TUMOR NECROSIS FACTOR-ALPHA; WOUND HEALING;

EID: 3342881856     PISSN: 10711007     EISSN: None     Source Type: Journal    
DOI: 10.1177/107110070402500510     Document Type: Article

References (21)

1. Alldred, A: Etanercept in rheumatoid arthritis. Expert Opin. Pharmacother. 7:1137-1148, 2001.
2. Baghai, M; Osmon, DDR; Wolk, DM; Wold, LE; Haidukewych, GJ: Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. Mayo Clin. Proc. 76:653-656, 2001.
3. Bathon, JM; Martin, RW; Fleischmann, RM; et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343:1586-1593, 2000.
4. Bibbo, C; Anderson, RB; Davis, WH; Norton, J: Complications in rheumatoid foot and ankle reconstructive surgery: analysis of 718 procedures in 103 patients. Foot Ankle Int. 24:40-44, 2003.
5. Brion, PH; Mittal-Henkle, A; Kalunian, KC: Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann. Intern. Med. 131:634, 1999.
6. Cunnane, G; Warnock, M; Fye, KH; Daikh, DI: Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. 47:445-449, 2002.
7. Ferraccioli, G; Mecchia, F; Di Poi, E; Fabris, M: Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. Ann. Rheum. Dis. 61: 358-361, 2002.
8. Fleischman, R; Iqbal, I; Nandeshwar, P; Quiceno, A: Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Say 25:173-197, 2002.
9. Galaria, NA; Werth, VP; Schumacher, HR: Leukocytoclastic vasculitis due to etanercept. J. Rheumatol. 27:2041-2044, 2000.
10. Garrison, L; McDonnell, ND: Etanercept: therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. 58(suppl I): 165-169, 1999.
11. Genovese, MC; Bathon, JM; Martin, RW; et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 46:1443-1450, 2002.
12. Gorman, JD; Sack, KE; Davis, JC, Jr: Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N. Engl. J. Med. 346:1349-1356, 2002.
13. Iyer, S; Yamauchi, P; Lowe, NJ: Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. Br. J. Dermatol. 146:118-121, 2002.
14. Lee, JH; Slifman, NR; Gershon, SK; et al.: Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis alpha antagonists infliximab and etanercept. Arthritis Rheum. 46: 2565-2570, 2002.
15. Mease, PJ; Goffe, BS; Metz, J; VanderStoep, A; Finck, B; Burge, DJ: Etanercept in the treatment of psoriatic arthritis and psoriasis. Lancet 356:385-390, 2000.
16. Moreland, LW; Bucy, RP; Weinblatt, ME; Mohler, KM; Spencer-Green, GT; Chatham, WW: Immune function in patients with rheumatoid arthritis treated with etanercept. Clin. Immunol. 103: 13-21, 2002.
17. Moreland, LW; Cohen, SB; Baumgartner, SW; et al.: Long-tem safety and efficacy of etanercept in patients with rheumatoid arthritis. J. Rheumatol. 28:1238-1244, 2001.
18. Phillips, K; Husni, ME; Karlson, EW; Coblyn, JS: Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum. 47:1-4, 2002.
19. Weinblatt, ME; Kremer, JM; Bankhurst, AD; et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. 340:253-259, 1999.
20. Yazici, Y; Erkan, D; Kulman, I; Belostocki, K; Harrison, MJ: Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world." Ann. Rheum. Dis. 61:638-640, 2002.
21. Yazici, Y; Erkan, D; Lockshin, MD: A preliminary study of etanercept in the treatment of severe resistant psoriatic arthritis. Clin. Exp. Rheumatol. 18:732-734, 2000.